Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 14, 2018. The document serves as a report of a foreign issuer regarding a significant corporate action rather than a periodic financial results report.
Key Financial Metrics
The filing text does not provide a clear value for GSK's revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a proposed acquisition.
- Transaction Price: $75.00 per share in cash.
- Target Company: TESARO, Inc. (NASDAQ: TRSO).
- Supporting Stockholder Ownership: Approximately 25.7% of TESARO's issued and outstanding shares as of December 10, 2018.
Material Changes
The primary material change is the commencement of a cash tender offer for all issued and outstanding shares of TESARO, Inc. This action follows a previously announced Agreement and Plan of Merger dated December 3, 2018. GSK, along with its subsidiary Adriatic Acquisition Corporation (AAC), has filed a tender offer statement on Schedule TO with the SEC.
Guidance, Outlook, and Risks
Transaction Timeline and Conditions:
- The tender offer commenced on December 14, 2018, and is scheduled to expire at 11:59 P.M. Eastern Time on January 14, 2019, unless extended or terminated.
- Closing conditions include the tender of at least one share more than 50% of TESARO's outstanding shares and the receipt of required regulatory approvals, including the expiration of the Hart-Scott-Rodino waiting period.
- Following the tender offer, AAC intends to acquire remaining shares through a merger at the same price.
Risks and Contingencies:
- The transaction is subject to customary closing conditions and regulatory approvals.
- Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections, as detailed in GSK's 2017 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the final tender offer statement on Schedule TO and TESARO's Schedule 14D-9 for complete terms and conditions.
- Confirm the status of regulatory approvals, specifically the Hart-Scott-Rodino waiting period.
- Monitor the percentage of shares tendered to ensure the 50% + 1 share closing condition is met.
- Review the recommendation of TESARO's board of directors regarding the tender offer.